Share This Page
Drug Price Trends for AIRSUPRA
✉ Email this page to a colleague

Average Pharmacy Cost for AIRSUPRA
Drug Name | NDC | Price/Unit ($) | Unit | Date |
---|---|---|---|---|
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 43.92067 | GM | 2025-01-01 |
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 42.64143 | GM | 2024-12-18 |
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 42.65639 | GM | 2024-11-20 |
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 42.67034 | GM | 2024-10-23 |
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 42.70703 | GM | 2024-08-21 |
AIRSUPRA 90-80 MCG INHALER | 00310-9080-12 | 42.71323 | GM | 2024-07-17 |
>Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Market Analysis and Price Projections for AIRSUPRA
Introduction to AIRSUPRA
AIRSUPRA, a combination of albuterol and budesonide, is a recently approved inhalation aerosol for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks in patients with asthma aged 18 years and older. This medication represents a significant advancement in asthma management, combining a short-acting selective beta2-adrenergic agonist (albuterol) and a synthetic corticosteroid (budesonide)[1].
Market Size and Growth Projections
The U.S. asthma drugs market, in which AIRSUPRA is a key player, is projected to experience substantial growth. As of 2023, the market was valued at USD 8.95 billion and is expected to surpass USD 14.75 billion by 2033, registering a Compound Annual Growth Rate (CAGR) of 5.12%[4].
The approval of AIRSUPRA has marked a significant milestone in this market. Given its efficacy in reducing the risk of severe asthma exacerbations and its innovative formulation as a pressurized metered-dose inhaler (pMDI), AIRSUPRA is poised to capture a significant share of the market. The adult segment, where AIRSUPRA has shown particular efficacy, is expected to maintain its market leadership throughout the forecast period[4].
Competitive Landscape
AIRSUPRA faces competition from other emerging therapies in the asthma market. However, its unique combination of albuterol and budesonide sets it apart. Clinical studies have demonstrated a statistically significant reduction in the risk of severe asthma exacerbations compared to traditional albuterol treatments, making it a preferred option for many patients[3].
Other emerging products, such as TEZSPIRE approved for self-administration in a pre-filled pen, will also compete in the market. However, AIRSUPRA's first-in-class status as an anti-inflammatory rescue medication positions it strongly against competitors[4].
Regulatory and Developmental Milestones
The FDA approval of AIRSUPRA in January 2023 was a crucial milestone. The drug has undergone extensive clinical trials, including the Phase IIIb BATURA trial, which was halted early due to its overwhelming efficacy in reducing severe asthma exacerbations. This regulatory success, combined with ongoing developmental activities, underscores the current and future market potential of AIRSUPRA[1][3].
Pricing and Cost Considerations
The current cost for AIRSUPRA inhalation aerosol is around $510 for a supply of 10.7 grams, making it a significant expense for patients. However, this cost can be mitigated through discount programs and patient assistance initiatives. For instance, the Drugs.com Discount Card can save patients up to 80% on prescription medicines, including AIRSUPRA[2].
In an effort to address high prescription drug prices, President Joe Biden and Senator Bernie Sanders have been advocating for a $35 monthly price cap on asthma inhalers. While this initiative does not directly apply to AIRSUPRA at the moment, it reflects broader efforts to make asthma medications more affordable. Major pharmaceutical companies, including AstraZeneca, have announced plans to implement similar price caps on their inhaler products, which could influence future pricing strategies for AIRSUPRA[5].
Financial Performance and Investor Confidence
AstraZeneca, the manufacturer of AIRSUPRA, has demonstrated strong financial performance and investor confidence. The company's revenue growth of 10.45% over the last twelve months and 13.33% in the most recent quarter highlights its ability to capitalize on innovative products like AIRSUPRA. With a gross profit margin of 82.62% and an operating income margin of 25.13%, AstraZeneca shows efficient cost management and the ability to translate research successes into financial gains[3].
Market Forecast Analysis
The forecasted sales data for AIRSUPRA from 2024 to 2032 indicates a promising market trajectory. The report provides comprehensive insights into the market scenario, including SWOT analysis, analysts’ views, and a comprehensive overview of market competitors. This analysis will support clients in their decision-making process regarding their therapeutic portfolio and help identify the overall scenario of AIRSUPRA in the asthma market[1].
Emerging Trends and Opportunities
The asthma drugs market is expected to evolve significantly due to extensive research and incremental healthcare spending worldwide. Companies are developing therapies that focus on novel approaches to treat and improve asthma conditions, which could present both challenges and opportunities for AIRSUPRA. The launch of late-stage emerging therapies in the near future will significantly impact the market, and AIRSUPRA's position will depend on its ability to adapt and innovate[1].
Conclusion
AIRSUPRA is poised to play a significant role in the asthma drugs market due to its innovative formulation, efficacy in reducing severe asthma exacerbations, and strong market support from AstraZeneca. While it faces competition and pricing challenges, the drug's unique benefits and the company's financial strength position it for continued growth.
Key Takeaways
- Market Growth: The U.S. asthma drugs market is projected to grow from USD 8.95 billion in 2023 to USD 14.75 billion by 2033.
- Efficacy: AIRSUPRA has shown a statistically significant reduction in the risk of severe asthma exacerbations compared to traditional albuterol treatments.
- Pricing: The current cost of AIRSUPRA is around $510 for a supply of 10.7 grams, with potential for cost reduction through discount programs and future price caps.
- Competitive Landscape: AIRSUPRA faces competition from other emerging therapies but is well-positioned due to its unique combination of albuterol and budesonide.
- Financial Performance: AstraZeneca's strong financial performance and investor confidence support the market potential of AIRSUPRA.
FAQs
Q: What is AIRSUPRA and how does it work?
AIRSUPRA is an inhalation aerosol that combines albuterol and budesonide for the as-needed treatment or prevention of bronchoconstriction and to reduce the risk of asthma attacks. It works by relaxing the muscles and reducing inflammation in the lung airways.
Q: Who is the target population for AIRSUPRA?
AIRSUPRA is approved for patients with asthma aged 18 years and older.
Q: What are the key benefits of AIRSUPRA compared to traditional treatments?
AIRSUPRA has shown a significant reduction in the risk of severe asthma exacerbations and reduces systemic corticosteroid exposure compared to albuterol.
Q: How much does AIRSUPRA cost, and are there any discount programs available?
The cost for AIRSUPRA is around $510 for a supply of 10.7 grams. Discount programs like the Drugs.com Discount Card can save patients up to 80% on prescription medicines.
Q: What are the future market projections for AIRSUPRA?
The market forecast analysis indicates a promising trajectory for AIRSUPRA from 2024 to 2032, with the drug expected to play a significant role in the asthma drugs market.
Sources
- Research and Markets, "AIRSUPRA Market Size, Insight, and Forecast to 2032".
- Drugs.com, "Airsupra Prices, Coupons, Copay Cards & Patient Assistance".
- Investing.com, "AstraZeneca's new asthma medication shows significant benefits".
- BioSpace, "U.S. Asthma Drugs Market Size to Surpass USD 14.75 Bn by 2033".
- AJMC, "Biden Administration Extends Efforts for $35 Monthly Asthma Inhaler Price Cap".
More… ↓